Author Index

Aaberge, I.S., Steinsvik, T.E., Groeng, E.-C., Leikvold, R.-B. & Løvik, M. Human antibody response to a pneumococcal vaccine in SCID-PBL-hu mice and simultaneously vaccinated human cell donors, 12

Abatangelo, C. *see* Mathov, I.

Abedi, M.R. Hammarström, L. Broomé, U. Angelin, B. Edvard Smith, C.I. & Christensson, B. Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC), 266

Abinun, M. *see* Lilic, D.

Abinun, M. *see* Lilic, D.

Afani, A. *see* Plotnicky-Gilquin, H.

Agostini, C. *see* Zambello, R.

Ahmad, R.U. *see* Wolf, H.M.

Ajjan, R.A. Watson, P.F. Mcintosh, R.S. & Weetman, A.P. Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis, 523

Ajmani, A.K. *see* Satoh, M.

Akasaka, J. *see* Maekawa, T.L.

Alavi, A. *see* Bond, A.

Alison, M.R. *see* Ravirajan, C.T.

Allen, M.E. *see* Carruthers, D.M.

Amlot, P.L., Tahami, F., Chinn, D. & Rawlings, E. Activation antigen expression on human T cells.I.Analysis by two-colour flow cytometry of umbilical cord blood, adult blood and lymphoid tissue, 176

Amoroso, A. *see* Gabrielli, A.

Angelin, B. *see* Abedi, M.R.

Anilkumar, T.V. *see* Ravirajan, C.T.

Arnett, F.C. *see* Moulds, J.M.

Asea, A., Hansson, M., Czerkinsky, C., Houze, T., Hermodsson, S., Strannegård, Ö. & Hellstrand, K. Histaminergic regulation of interferon-gamma (IFN-γ) production by human natural killer (NK) cells, 376

Aulak, K.S. *see* Malek, R.

Aust, G., Heuer, M., Laue, S., Lehmann, I., Hofmann, A., Heldin, N.-E. & Scherbaum, W.A. Expression of tumour necrosis factor-alpha (TNF-α) mRNA and protein in pathological thyroid tissue and carcinoma cell lines, 148

Autenrieth, I.B. *see* Noll, A.

Axford, J.S. *see* Bond, A.

Bacon, P.A. *see* Carruthers, D.M.

Baharav, E., Merimski, O., Shoenfeld, Y., Zigelman, R., Gilbrud, B., Yecheskel, G., Youinou, P. & Fishman, P. Tyrosinase as an autoantigen in patients with vitiligo, 84

Bailey, R.L. *see* Holland, M.J.

Bakker, M.A.H. *see* Heeringa, P.

Banla, M. *see* Lüder, C.G.K.

Barbosa, J.E. *see* Teixeira, J.E.

Barcellini, W. *see* Di marco, R.

Barker, R.N. *see* De sá oliveira, G.G.

Barral, A. *see* Brodskyn, C.I.

Barral-Netto, M. *see* Brodskyn, C.I.

Behboudi, S., Morein, B. & Villacres-Eriksson, M. *In vitro* activation of antigen-presenting cells (APC) by defined composition of *Quillaja saponaria* Molina triterpenoids, 26

Beijleveld, L.J.J. Groen, H., Broeren, C.P.M., Klatter, F.A., Kampinga, J., Damoiseaux, J.G.M.C. & Van breda vriesman, P.J.C. Susceptibility to clinically manifest cyclosporine A (CsA)-induced autoimmune disease is associated with interferon-gamma (IFN-γ)-producing $CD45RC^+$ $RT6^-$ T helper cells, 486

Bendtzen, K. *see* Jakobsen, P.H.

Berden, J.H.M. *see* Heeringa, P.

Berden, J.H.M. *see* Van bruggen, M.C.J.

Bergasa, N.V. *see* Shindo, M.

Bhat, N.M., Bieber, M.M., Stevenson, F.K. & Teng, N.N.H. Rapid cytotoxicity of human B lymphocytes induced by VH4-34 (VH4.21) gene-encoded monoclonal antibodies, 183

Bieber, M.M. *see* Bhat, N.M.

Böcher, W.O., Herzog-Hauff, S., Herr, W., Heermann, K., Gerken, G., Meyer zum Büschenfelde, K.-H. & Löhr, H.F. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response *in vitro* in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection, 52

Bogstedt, A.K., Nava, S., Wadström, T. & Hammarström, L. *Helicobacter pylori* infections in IgA deficiency: lack of role for the secretory immune system, 202

Boirivant, M. *see* Luzzati, A.L.

Bond, A., Alavi, A., Axford, J.S., Youinou, P. & Hay, F.C. The relationship between exposed galactose and N-acetylglucosamine residues on IgG in rheumatoid arthritis (RA), juvenile chronic arthritis (JCA) and Sjögren's syndrome (SS), 99

Borghi, M. *see* Reali, E.

Brander, C., Corradin, G., Hasler, T. & Pichler, W.J. Peptide immunization in humans: a combined $CD8^+$/$CD4^+$ T cell-targeted vaccine restimulates the memory CD4 T cell response but fails to induce cytotoxic T lymphocytes (CTL), 18

Braun-Elwert, L. *see* Shindo, M.

Brodskyn, C.I., Barral, A., Bulhões, M.A., Souto, T., Machado, W.C. & Barral-Netto, M. Cytotoxicity in patients with different clinical forms of Chagas' disease, 450

Broeren, C.P.M. *see* Beijleveld, L.J.J.

Broomé, U. *see* Abedi, M.R.

Brouwer, E. *see* Heeringa, P.

Brown, C.M. *see* Moyes, S.P.

Brown, K.A. *see* Vora, A.J.

Brown, K.A. *see* Watson, C.

Bruner, J.M. *see* Roussel, E.

Brunmark, C. *see* Hellmark, T.

Bulhões, M.A. *see* Brodskyn, C.I.

Burgmann, H. *see* Wenisch, C.

Byrne, G.I. *see* Holland, M.J.

Caffau, C. *see* Zanussi, S.

Calvert, J.E. *see* Lilic, D.

Candela, M. *see* Gabrielli, A.

Cant, A.J. *see* Lilic, D.

Capron, A. *see* Cottrez, F.

Carlsten, H. *see* Nilsson, N.

Carruthers, D.M., Naylor, W.G., Allen, M.E., Kitas, G.D., Bacon, P.A. & Young, S.P. Characterization of altered calcium signalling in T lymphocytes from patients with rheumatoid arthritis (RA), 291

Carter, D.C. *see* Gough, D.B.

Carter, T.H. *see* Satoh, M.

Casadevall, A. *see* Paizi, G.

Chapman, C.J., Mockridge, C.I., Hamblin, T.J. & Stevenson, F.K. Tracking of the V_{4-34} (V_H4–21) gene in human tonsil reveals clonal isotype switch events and a highly variable degree of somatic hypermutation, 360

Cheillan, F. *see* Erregragui, K.

Chersi, A. *see* Luzzati, A.L.

Cherubini, G. *see* Gabrielli, A.

Chinn, D. *see* Amlot, P.L.

Christensson, B. *see* Abedi, M.R.

Cipriani, A. *see* Zambello, R.

Clancy, R.L. *see* Gleeson, M.

Clementi, M. *see* Gabrielli, A.

CLERICI, M. *see* ZANUSSI, S.
COLLINS, M.K.L. *see* DE WIT, D.
CONWAY, D.J. *see* HOLLAND, M.J.
CORRADIN, G. *see* BRANDER, C.
COSTA, R.S. *see* TEIXEIRA, J.E.
COTTREZ, F., CAPRON, A. & GROUX, H. Selective CD4$^+$ T cell deletion after specific activation in HIV-infected individuals; protection by anti-CD28 monoclonal antibodies, 31
COUTINHO, R.A. *see* ROOS, M.TH.L.
CRIPPS, A.W. *see* GLEESON, M.
CSERNOK, E., SZYMKOWIAK, C.H., MISTRY, N., DAHA, M.R., GROSS, W.L. & KEKOW, J. Transforming growth factor-beta (TGF-β) expression and interaction with proteinase 3 (PR3) in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, 104
CULLEY, F. *see* HOLLAND, M.J.
CZERKINSKY, C. *see* ASEA, A.

D'ALESSANDRO, U. *see* JAKOBSEN, P.H.
D'ANDREA, M. *see* ZANUSSI, S.
DAHA, M.R. *see* CSERNOK, E.
DAHA, M.R. *see* FIJEN, C.A.P.
DAHA, M.R. *see* HEERINGA, P.
DAMOISEAUX, J.G.M.C. *see* BEIJLEVELD, L.J.J.
DANKERT, J. *see* FIJEN, C.A.P.
DAVIDSON, R.N. *see* JURCEVIC, S.
DAVIS III, A.E. *see* MALEK, R.
DE LEEUW
DE PAOLI, P. *see* ZANUSSI, S.
DE SÁ OLIVEIRA, G.G., IZUI, S., RAVIRAJAN, C.T., MAGEED, R.A.K., LYDYARD, P.M., ELSON, C.J. & BARKER, R.N. Diverse antigen specificity of erythrocyte-reactive monoclonal autoantibodies from NZB mice, 313
DE WIT, D., FLEMMING, C.L., HARRIS, J.D., PALMER, K.J., MOORE, J.S., GORE, M.E. & COLLINS, M.K.L. IL-12 stimulation but not B7 expression increases melanoma killing by patient cytotoxic T lymphocytes (CTL), 353
DEFOORT, J.P. *see* ERREGRAGUI, K.
DESGRANGES, C. *see* PLOTNICKY-GILQUIN, H.
DI MARCO, R. ZACCONE, P. MAGRO, G., GRASSO, S., LUNETTA, M., BARCELLINI, W., NICOLOSI, V.M. MERONI, P.L. & NICOLETTI, F. Synergistic effect of deoxyspergualin (DSP) and cyclosporin A (CsA) in the prevention of spontaneous autoimmune diabetes in BB rats, 338
DI MODUGNO, F. *see* LUZZATI, A.L.
DOLMAN, K.M. *see* HEERINGA, P.
DOMSCHKE, W. *see* LÜGERING, N.
DUMONDE, D.C. *see* VORA, A.J.
DUMONDE, D.C. *see* WATSON, C.

EBERT, E.C. & ROBERTS, A.I. IL-4 down-regulates the responsiveness of human intraepithelial lymphocytes, 556
EDVARD SMITH, C.I. *see* ABEDI, M.R.
EDWARDS, B. *see* SCHUYLER, M.
EIBL, M.M. *see* WOLF, H.M.
ELASED, K.M. TAVERNE, J. & PLAYFAIR, J.H.L. Malaria, blood glucose, and the role of tumour necrosis factor (TNF) in mice, 443
ELSON, C.J. *see* DE SÁ OLIVEIRA, G.G.
ENTHAMMER, C. *see* ZAMBELLO, R.
ERREGRAGUI, K., CHEILLAN, F., DEFOORT, J.P., PRATO, S. & FERT, V. Autoantibodies to thyroid hormones: the role of thyroglobulin, 140
EXNER, M. *see* WENISCH, C.

FAITH, A., YSSEL, H., O'HEHIR, R.E. & LAMB, J.R. Reversal of the inhibitory effects of HIV-gp120 on CD4$^+$ T cells by stimulation through the CD28 pathway, 225
FALK, R.J. *see* YANG, J.J.
FARRANT *MRC*, J. *see* NORTH, M.E.
FEARON, K.C.H. *see* GOUGH, D.B.
FERT, V. *see* ERREGRAGUI, K.
FIJEN, C.A.P., KUIJPER, E.J., TE BULTE, M.T., VAN DE HEUVEL, M.M., HOLDRINET, A.C.J.M., SIM, R.B., DAHA, M.R. & DANKERT, J. Heterozygous and homozygous factor H deficiency states in a Dutch family, 511
FISAHN, M. *see* LÜGERING, N.
FISCHER, M.B. *see* WOLF, H.M.
FISHMAN, P. *see* BAHARAV, E.
FLEMMING, C.L. *see* DE WIT, D.
FRICKER, P.A. *see* GLEESON, M.
FUJIHARA, M. *see* MAEKAWA, T.L.
FUJIKAWA, S. *see* MAEKAWA, T.L.
FUJIMOTO, M., SATO, S., IHN, H., TAMAKI, T., KIKUCHI, K., SOMA, Y. & TAMAKI, K. Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma, 297
FUJIMOTO, M. *see* IHN, H.
FUKUCHI, K. *see* ISHIYAMA, T.
FUNAUCHI, M. *see* NORTH, M.E.

GABAY, C., SINGWE, M., GENIN, B., MEYER, O., MENTHA, G., LE COULTRE, C., VISCHER, T. & GUERNE, P.-A. Circulating levels of IL-11 and leukaemia inhibitory factor (LIF) do not significantly participate in the production of acute-phase proteins by the liver, 260
GABRIELLI, A., ZHANG, Z.-X., CHERUBINI, G., CANDELA, M., SAVOLDI, S., MANZIN, A., CLEMENTI, M., AMOROSO, A. & SALLBERG, M. Differential humoral immune response against hepatitis C virus antigenic synthetic peptides in infected patients with and without mixed cryoglobulinaemia, 59
GALIMBERTI, R. *see* MATHOV, I.
GANAPATI, R. *see* RIECKMANN, P.
GAVIOLI, R. *see* REALI, E., GUERRINI, R.
GENIN, B. *see* GABAY, C.
GEORGOPOULOS, A. *see* WENISCH, C.
GERKEN, G. *see* BÖCHER, W.O.
GIACOMINI, E. *see* LUZZATI, A.L.
GILBRUD, B. *see* BAHARAV, E.
GINGRAS, M.C. *see* ROUSSEL, E.
GIORDANI, L. *see* LUZZATI, A.L.
GIORI, B. *see* REALI, E.
GLEESON, M., PYNE, D.B., MCDONALD, W.A., CLANCY, R.L., CRIPPS, A.W., HORN, P.L. & FRICKER, P.A. Pneumococcal antibody responses in elite swimmers, 238
GOERDT, S., KODELJA, V., SCHMUTH, M., ORFANOS, C.E. & SORG, C. The mononuclear phagocyte–dendritic cell dichotomy: myths, facts, and a revised concept, 1
GOLDING, M.C.H. *see* RAVIRAJAN, C.T.
GORE, M.E. *see* DE WIT, D.
GOTT, K. *see* SCHUYLER, M.
GOUGH, D.B., FEARON, K.C.H. & CARTER, D.C. Metabolic disturbance and sensitivity to endotoxin in patients with advanced cancer: relationship to lymphocyte reactivity, tumour necrosis factor (TNF) production and survival, 529
GRANIER, C. *see* SAÏ, P.
GRANINGER, W. *see* WENISCH, C.
GRASSO, S. *see* DI MARCO, R.
GREENWOOD, B.M. *see* JAKOBSEN, P.H.
GRIMM, E.A. *see* ROUSSEL, E.
GROEN, H. *see* BEIJLEVELD, L.J.J.
GROENG, E.-C. *see* AABERGE, I.S.
GROSS, W.L. *see* CSERNOK, E.
GROUX, H. *see* COTTREZ, F.
GRUBECK-LOEBENSTEIN, B. *see* STEGER, M.M.
GUERNE, P.-A. *see* GABAY, C.
GULLE, H. *see* WOLF, H.M.

HAERTLÉ, TH. *see* SAÏ, P.
HAHN-ZORIC, M. *see* ULANOVA, M.
HAMBLIN, T.J. *see* CHAPMAN, C.J.
HAMMARSTRÖM, L. *see* BOGSTEDT, A.K.
HAMMARSTRÖM, L. *see* ABEDI, M.R.
HANSON, L.Å. *see* ULANOVA, M.
HANSSON, M. *see* ASEA, A.
HARRIS, J.D. *see* DE WIT, D.
HARVEY, G.R. RANDS, A.L. & MCHUGH, N.J. Anti-RNA polymerase antibodies in systemic sclerosis (SSc): association with anti-topoisomerase I antibodies and identification of autoreactive subunits of RNA polymerase II, 468
HASLER, T. *see* BRANDER, C.
HAUBER, I. *see* WOLF, H.M.

HAY, F.C. *see* BOND, A.
HEERINGA, P., VAN DEN BORN, J., BROUWER, E., DOLMAN, K.M., KLOK, P.A., HUITEMA, M.G., LIMBURG, P.C., BAKKER, M.A.H., BERDEN, J.H.M., DAHA, M.R. & KALLENBERG, C.G.M. Elastase, but not proteinase 3 (PR3), induces proteinuria associated with loss of glomerular basement membrane heparan sulphate after *in vivo* renal perfusion in rats, 321
HEERMANN, K. *see* BÖCHER, W.O.
HELDIN, N.-E. *see* AUST, G.
HELLMARK, T., BRUNMARK, C., TROJNAR, J. & WIESLANDER, J. Epitope mapping of anti-glomerular basement membrane (GBM) antibodies with synthetic peptides, 504
HELLSTRAND, K. *see* ASEA, A.
HENDERSON, D.C. *see* JURGES, E.S.
HERMODSSON, S. *see* ASEA, A.
HERR, W. *see* BÖCHER, W.O.
HERZOG-HAUFF, S. *see* BÖCHER, W.O.
HEUER, M. *see* AUST, G.
HILLS, A. *see* JURCEVIC, S.
HOFMANN, A. *see* AUST, G.
HOLDRINET, A.C.J.M. *see* FIJEN, C.A.P.
HOLLAND, M.J., BAILEY, R.L., CONWAY, D.J., CULLEY, F., MIRANPURI, G., BYRNE, G.I., WHITTLE, H.C. & MABEY, D.C.W. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC) responses to antigens of *Chlamydia trachomatis* in subjects with severe trachomatous scarring, 429
HORN, P.L. *see* GLEESON, M.
HOUZE, T. *see* ASEA, A.
HUITEMA, M.G. *see* HEERINGA, P.
HYLKEMA, M.N. *see* VAN BRUGGEN, M.C.J.

IGARASHI, A. *see* IHN, H.
IHN, H. *see* FUJIMOTO, M.
IHN, H. SATO, S. FUJIMOTO, M. KIKUCHI, K. IGARASHI, A. SOMA, Y. TAMAKI, K. & TAKEHARA, K. Measurement of anticardiolipin antibodies by ELISA using β_2-glycoprotein I (β_2-GPI) in systemic sclerosis, 475
ISENBERG, D.A. *see* RAVIRAJAN, C.T.
ISHIYAMA, T., KOIKE, M., WATANABE, K., WATANABE, H., FUKUCHI, K., & TSURUOKA, N. Natural killer (NK) lymphocytosis induced by Epstein–Barr virus (EBV) reactivation in monoclonal gammopathy of undetermined significance (MGUS), 46
IVANYI, J. *see* JURCEVIC, S.
IVORY, K. *see* NORTH, M.E.
IWAI, T., MURO, Y., SUGIMOTO, K., MATSUMOTO, Y. & OHASHI, M. Clinical features of anti-chromo antibodies associated with anti-centromere antibodies, 285
IZUI, S. *see* DE SÁ OLIVEIRA, G.G.

JAKOBSEN, P.H., MCKAY, V., N'JIE, R., OLALEYE, B.O., D'ALESSANDRO, U., BENDTZEN, K., SCHOUSBOE, I. & GREENWOOD, B.M. Soluble products of inflammatory reactions are not induced in children with asymptomatic *Plasmodium falciparum* infections, 69
JENNETTE, J.C. *see* YANG, J.J.
JONES, E.A. *see* SHINDO, M.
JURCEVIC, S., HILLS, A., PASVOL, G., DAVIDSON, R.N., IVANYI, J. & WILKINSON, R.J. T cell responses to a mixture of *Mycobacterium tuberculosis* peptides with complementary HLA-DR binding profiles, 416
JURGES, E.S. & HENDERSON, D.C. Inflammatory and immunological markers in preterm infants: correlation with disease, 551

KALLENBERG, C.G.M. *see* HEERINGA, P.
KAMPINGA, J. *see* BEIJLEVELD, L.J.J.
KEKOW, J. *see* CSERNOK, E.
KIKUCHI, K. *see* FUJIMOTO, M.
KIKUCHI, K. *see* IHN, H.
KITAS, G.D. *see* CARRUTHERS, D.M.
KLATTER, F.A. *see* BEIJLEVELD, L.J.J.
KLOK, P.A. *see* HEERINGA, P.
KODELJA, V. *see* GOERDT, S.
KOIKE, M. *see* ISHIYAMA, T.
KRAMERS, C. *see* VAN BRUGGEN, M.C.J.
KUCHARZIK, T. *see* LÜGERING, N.
KUIJPER, E.J. *see* FIJEN, C.A.P.

LACHMANN, P.J. *see* TEIXEIRA, J.E.
LAMB, J.R. *see* FAITH, A.
LANE, A.C. *see* NORTH, M.E.
LANE, P. Are polysaccharide antibody responses independent: the T cell enigma?, 10
LANGDON, J.J. *see* SATOH, M.
LANGE, J.M.A. *see* ROOS, M.TH.L.
LAU, Y.L. *see* ULANOVA, M.
LAUE, S. *see* AUST, G.
LE COULTRE, C. *see* GABAY, C.
LEHMANN, I. *see* AUST, G.
LEIKVOLD, R.-B. *see* AABERGE, I.S.
LEONI, J. *see* MATHOV, I.
LILIC, D., CALVERT, J.E., CANT, A.J., ABINUN, M. & SPICKETT, G.P. Chronic mucocutaneous candidiasis. II.Class and subclass of specific antibody responses *in vivo* and *in vitro*, 213
LILIC, D. CANT, A.J. ABINUN, M. CALVERT, J.E. & SPICKETT, G.P. Chronic mucocutaneous candidiasis. I.Altered antigen-stimulated IL-2, IL-4, IL-6 and interferon-gamma (IFN-γ) production, 205
LIMBURG, P.C. *see* HEERINGA, P.
LÖHR, H.F. *see* BÖCHER, W.O.
LOOAREESUWAN, S. *see* WENISCH, C.
LØVIK, M. *see* AABERGE, I.S.
LUCAS, A. *see* ULANOVA, M.
LUNETTA, M. *see* DI MARCO, R.
LUZZATI, A.L. BOIRIVANT, M. GIACOMINI, E. GIORDANI, L. DI MODUGNO, F. & CHERSI, A. Interferon-gamma (IFN-γ) can counteract the *in vitro* inhibitory effect of an HIV p24 immunosuppressive hepta-peptide, 403
LÜDER, C.G.K., SCHULZ-KEY, H., BANLA, M., PRITZE, S. & SOBOSLAY, P.T. Immunoregulation in onchocerciasis: predominance of Th1-type responsiveness to low molecular weight antigens of *Onchocerca volvulus* in exposed individuals without microfilaridermia and clinical disease, 245
LÜGERING, N., KUCHARZIK, T., FISAHN, M., DOMSCHKE, W. & STOLL, R. Crohn's disease (CD) patients suffering from peripheral arthritis or ankylosing spondylitis reveal restricted T cell receptor Vβ regions in different temporal phases of disease, 278
LYDYARD, P.M. *see* DE SÁ OLIVEIRA, G.G.

MCGEE, D.W. & VITKUS, S.J.D. IL-4 enhances IEC-6 intestinal epithelial cell proliferation yet has no effect on IL-6 secretion, 274
MCHUGH, N.J. *see* HARVEY, G.R.
MABEY, D.C.W. *see* HOLLAND, M.J.
MACHADO, W.C. *see* BRODSKYN, C.I.
MACZEK, C. *see* STEGER, M.M.
MAEKAWA, T.L., TAKAHASHI, T.A., FUJIHARA, M., AKASAKA, J., FUJIKAWA, S., MINAMI, M. & SEKIGUCHI, S. Effects of ultraviolet B irradiation on cell–cell interaction; implication of morphological changes and actin filaments in irradiated cells, 389
MAGEED, R.A.K. *see* DE SÁ OLIVEIRA, G.G.
MAGEED, R.A. *see* MOYES, S.P.
MAGRO, G. *see* DI MARCO, R.
MAINI, R.N. *see* MOYES, S.P.
MALEK, R., AULAK, K.S. & DAVIS III, A.E. The catabolism of intact, reactive centre-cleaved and proteinase-complexed C1 inhibitor in the guinea pig, 191
MANZIN, A. *see* GABRIELLI, A.
MARASTONI, M. *see* REALI, E.
MARTIGNAT, L. *see* SAÏ, P.
MASUCCI, M.G. *see* REALI, E.
MATHOV, I., PLOTKIN, L., ABATANGELO, C., GALIMBERTI, R., SQUIQUERA, L. & LEONI, J. Antibodies from patients with psoriasis recognize N-acetylglucosamine terminals in glycoproteins from *Pityrosporum ovale*, 79
MATSUMOTO, Y. *see* IWAI, T.
MAZAR, S. *see* PAIZI, G.
MCCOY, T. *see* VORA, A.J.
MCDONALD, W.A. *see* GLEESON, M.
MCINTOSH, R.S. *see* AJJAN, R.A.
MCKAY, V. *see* JAKOBSEN, P.H.
MEINESZ, A.A.P. *see* ROOS, M.
MENTHA, G. *see* GABAY, C.
MERIMSKI, O. *see* BAHARAV, E.

MERONI, P.L. *see* DI MARCO, R.
MEYER ZUM BÜSCHENFELDE, K.-H. *see* BÖCHER, W.O.
MEYER, O. *see* GABAY, C.
MIEDEMA, F. *see* ROOS, M.TH.L.
MINAMI, M. *see* MAEKAWA, T.L.
MIRANPURI, G. *see* HOLLAND, M.J.
MISTRY, N. *see* CSERNOK, E.
MOCKRIDGE, C.I. *see* CHAPMAN, C.J.
MOORE, J.S. *see* DE WIT, D.
MOREIN, B. *see* BEHBOUDI, S.
MORI, K. *see* SOBAJIMA, J.
MOSER, R.P. *see* ROUSSEL, E.
MOULDS, J.M., REVEILLE, J.D. & ARNETT, F.C. Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) patients and normal controls of three ethnic groups, 302
MOYES, S.P., BROWN, C.M., SCOTT, B.B., MAINI, R.N. & MAGEED, R.A. Analysis of V_κ genes in rheumatoid arthritis (RA) synovial B lymphocytes provides evidence for both polyclonal activation and antigen-driven selection, 89
MUKHERJEE, S. *see* PAIZI, G.
MULLIN, G.E. *see* SHINDO, M.
MURO, Y. *see* IWAI, T.

N'JIE, R. *see* JAKOBSEN, P.H.
NAKAO, K. *see* SOBAJIMA, J.
NAKAO, K. *see* SUMITA, S.
NAVA, S. *see* BOGSTEDT, A.K.
NAYLOR, W.G. *see* CARRUTHERS, D.M.
NICOLETTI, F. *see* DI MARCO, R.
NICOLOSI, V.M. *see* DI MARCO, R.
NILSSON, N. & CARLSTEN, H. Enhanced natural but diminished antibody-mediated cytotoxicity in the lungs of MRL/*lpr*/*lpr* mice, 480
NOLL, A. & AUTENRIETH, I.B. *Yersinia*-hsp60-reactive T cells are efficiently stimulated by peptides of 12 and 13 amino acid residues in a MHC class II ($I\text{-}A^b$)-restricted manner, 231
NORTH, M.E., IVORY, K., FUNAUCHI, M., WEBSTER, A.D.B., LANE, A.C. & FARRANT *MRC*, J. Intracellular cytokine production by human $CD4^+$ and $CD8^+$ T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three-colour flow cytometry, 517
NUSSBAUM, G. *see* PAIZI, G.

O'DONOHUE, R. *see* WILLIAMS, J.
O'HEHIR, R.E. *see* FAITH, A.
OGASAWARA, T. *see* SATOH, M.
OHASHI, M. *see* IWAI, T.
OKAZAKI, T. *see* SOBAJIMA, J.
OKAZAKI, T. *see* SUMITA, S.
OLALEYE, B.O. *see* JAKOBSEN, P.H.
ORFANOS, C.E. *see* GOERDT, S.
OSAKADA, F. *see* SOBAJIMA, J.
OZAKI, S. *see* SOBAJIMA, J.
OZAKI, S. *see* SUMITA, S.

PAIZI, G. SPIRA, M. MAZAR, S. NUSSBAUM, G. MUKHERJEE, S. & CASADEVALL, A. Generation of biologically active anti-*Cryptococcus neoformans* IgG, IgE and IgA isotype switch variant antibodies by acridine orange mutagenesis, 436
PAKKER, N.G. *see* ROOS, M.TH.L.
PALMER, K.J. *see* DE WIT, D.
PARSCHALK, B. *see* WENISCH, C.
PASVOL, G. *see* JURCEVIC, S.
PERKIN, G.D. *see* VORA, A.J.
PICHLER, W.J. *see* BRANDER, C.
PLAYFAIR, J.H.L. *see* ELASED, K.M.
PLOTKIN, L. *see* MATHOV, I.
PLOTNICKY-GILQUIN, H., AFANI, A., VERNANT, J.C. & DESGRANGES, C. Complement-dependent cytotoxic antibodies to human T lymphotropic virus type I (HTLV-I)-infected cells in the sera of HTLV-I-infected individuals, 39
PRANGE, H.W. *see* RIECKMANN, P.
PRATO, S. *see* ERREGRAGUI, K.
PRITZE, S. *see* LÜDER, C.G.K.
PROFUMO, E. *see* RIGANÒ, R.
PYNE, D.B. *see* GLEESON, M.

RANDS, A.L. *see* HARVEY, G.R.
RAVIRAJAN, C.T. *see* DE SÁ OLIVEIRA, G.G.
RAVIRAJAN, C.T., SARRAF, C.E., ANILKUMAR, T.V., GOLDING, M.C.H., ALISON, M.R. & ISENBERG, D.A. An analysis of apoptosis in lymphoid organs and lupus disease in murine systemic lupus erythematosus (SLE), 306
RAWLINGS, E. *see* AMLOT, P.L.
REALI, E., GUERRINI, R., GIORI, B., BORGHI, M., MARASTONI, M., TOMATIS, R., TRANIELLO, S., MASUCCI, M.G. & GAVIOLI, R. Activation of epitope-specific memory cytotoxic T lymphocyte responses by synthetic peptides, 369
REEVES, W.H. *see* SATOH, M.
REVEILLE, J.D. *see* MOULDS, J.M.
RICHARDS, H.B. *see* SATOH, M.
RIECKMANN, P. SCHOLZE, G. WEICHSELBRAUN, I., GANAPATI, R. & PRANGE, H.W. Soluble adhesion molecules in sera of patients with leprosy: levels of soluble intercellular adhesion molecule-1 (sICAM-1) rapidly decrease during multi-drug therapy, 65
RIGANÒ, R. PROFUMO, E. TEGGI, A. & SIRACUSANO, A. Production of IL-5 and IL-6 by peripheral blood mononuclear cells (PBMC) from patients with *Echinococcus granulosus* infection, 456
RIVEREAU, A.S. *see* SAÏ, P.
ROBERTS, A.I. *see* EBERT, E.C.
ROOS, M.TH.L., MIEDEMA, F., MEINESZ, A.A.P., N.A.S.M. DE LEEUW, PAKKER, N.G., LANGE, J.M.A., COUTINHO, R.A. & SCHELLEKENS, P.TH.A. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression, 409
ROUSSEL, E., GINGRAS, M.C., GRIMM, E.A., BRUNER, J.M. & MOSER, R.P. Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas, 344

SAÏ, P. RIVEREAU, A.S. GRANIER, C., HAERTLÉ, TH. & MARTIGNAT, L. Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524–543 reduces cyclophosphamide-accelerated diabetes, 330
SALLBERG, M. *see* GABRIELLI, A.
SAMSTAG, A. *see* WOLF, H.M.
SARRAF, C.E. *see* RAVIRAJAN, C.T.
SATO, S. *see* FUJIMOTO, M.
SATO, S. *see* IHN, H.
SATOH, M., AJMANI, A.K., STOJANOV, L., LANGDON, J.J., OGASAWARA, T., WANG, J., DOOLEY, M.A., RICHARDS, H.B., WINFIELD, J.B., CARTER, T.H. & REEVES, W.H. Autoantibodies that stabilize the molecular interaction of Ku antigen with DNA-dependent protein kinase catalytic subunit, 460
SAVOLDI, S. *see* GABRIELLI, A.
SCHELLEKENS, P.TH.A. *see* ROOS, M.TH.L.
SCHERBAUM, W.A. *see* AUST, G.
SCHMUTH, M. *see* GOERDT, S.
SCHOLZE, G. *see* RIECKMANN, P.
SCHOUSBOE, I. *see* JAKOBSEN, P.H.
SCHULZ-KEY, H. *see* LÜDER, C.G.K.
SCHUYLER, M., GOTT, K. & EDWARDS, B. Experimental hypersensitivity pneumonitis: cellular requirements, 169
SCOTT, B.B. *see* MOYES, S.P.
SEKIGUCHI, S. *see* MAEKAWA, T.L.
SEMENZATO, G. *see* ZAMBELLO, R.
SHINDO, M., MULLIN, G.E., BRAUN-ELWERT, L., BERGASA, N.V., JONES, E.A. & JAMES, S.P. Cytokine mRNA expression in the liver of patients with primary biliary cirrhosis (PBC) and chronic hepatitis B (CHB), 254
SHOENFELD, Y. *see* BAHARAV, E.
SIM, R.B. *see* FIJEN, C.A.P.
SIMONELLI, C. *see* ZANUSSI, S.
SINGWE, M. *see* GABAY, C.
SIRACUSANO, A. *see* RIGANÒ, R.
SMEENK, R.J.T. *see* VAN BRUGGEN, M.C.J.
SMITH, N. *see* WATSON, C.
SOBAJIMA, J. *see* SUMITA, S.
SOBAJIMA, J., OZAKI, S., OKAZAKI, T., OSAKADA, F., SUMITA, S., MORI,

K. & NAKAO, K. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type, 120
SOBOSLAY, P.T. *see* LÜDER, C.G.K.
SOMA, Y. *see* FUJIMOTO, M.
SOMA, Y. *see* IHN, H.
SORG, C. *see* GOERDT, S.
SOUTO, T. *see* BRODSKYN, C.I.
SPICKETT, G.P. *see* LILIC, D.
SPIRA, M. *see* PAIZI, G.
SQUIQUERA, L. *see* MATHOV, I.
STEGER, M.M., MACZEK, C. & GRUBECK-LOEBENSTEIN, B. Morphologically and functionally intact dendritic cells can be derived from the peripheral blood of aged individuals, 544
STEINSVIK, T.E. *see* AABERGE, I.S.
STEPTOE, R.J. & THOMSON, A.W. Dendritic cells and tolerance induction, 397
STEVENSON, F.K. *see* BHAT, N.M.
STEVENSON, F.K. *see* CHAPMAN, C.J.
STOJANOV, L. *see* SATOH, M.
STOLL, R. *see* LÜGERING, N.
STRANNEGÅRD, Ö. *see* ASEA, A.
SUGIMOTO, K. *see* IWAI, T.
SUMITA, S. *see* SOBAJIMA, J.
SUMITA, S., OZAKI, S., OKAZAKI, T., SOBAJIMA, J. & NAKAO, K. A vascular smooth muscle-specific $CD4^+$ T cell line that induces pulmonary vasculitis in MRL-+/+ mice, 163
SZYMKOWIAK, C.H. *see* CSERNOK, E.

TAHAMI, F. *see* AMLOT, P.L.
TAKAHASHI, T.A. *see* MAEKAWA, T.L.
TAKEHARA, K. *see* IHN, H.
TAMAKI, K. *see* FUJIMOTO, M.
TAMAKI, K. *see* IHN, H.
TAMAKI, T. *see* FUJIMOTO, M.
TAVERNE, J. *see* ELASED, K.M.
TE BULTE, M.T. *see* FIJEN, C.A.P.
TEGGI, A. *see* RIGANÒ, R.
TEIXEIRA, J.E., COSTA, R.S., LACHMANN, P.J., WÜRZNER, R. & BARBOSA, J.E. CR1 stump peptide and terminal complement complexes are found in the glomeruli of lupus nephritis patients, 497
TENG, N.N.H. *see* BHAT, N.M.
THALHAMMER, F. *see* WENISCH, C.
TIRELLI, U. *see* ZANUSSI, S.
TOMATIS, R. *see* REALI, E.
TRANIELLO, S. *see* REALI, E.
TRENTIN, L. *see* ZAMBELLO, R.
TROJNAR, J. *see* HELLMARK, T.
TUTTLE, R. *see* YANG, J.J.

ULANOVA, M., HAHN-ZORIC, M., LAU, Y.L., LUCAS, A. & HANSON, L.Å. Expression of *Haemophilus influenzae* type b idiotype 1 on naturally acquired antibodies, 422

VAN BREDA VRIESMAN, P.J.C. *see* BEIJLEVELD, L.J.J.
VAN BRUGGEN, M.C.J., KRAMERS, C., HYLKEMA, M.N., SMEENK, R.J.T. & BERDEN, J.H.M. Significance of anti-nuclear and anti-extracellular matrix autoantibodies for albuminuria in murine lupus nephritis; a longitudinal study on plasma and glomerular eluates in MRL/l mice, 132
VAN DE HEUVEL, M.M. *see* FIJEN, C.A.P.
VAN DEN BORN, J. *see* HEERINGA, P.
VANIJANONTA, S. *see* WENISCH, C.
VERNANT, J.C. *see* PLOTNICKY-GILQUIN, H.
VILLACRES-ERIKSSON, M. *see* BEHBOUDI, S.
VISCHER, T. *see* GABAY, C.
VITKUS, S.J.D. *see* MCGEE, D.W.
VORA, A.J. *see* WATSON, C.
VORA, A.J., PERKIN, G.D., MCCOY, T., DUMONDE, D.C. & BROWN, K.A. Enhanced binding of lymphocytes from patients with multiple sclerosis to tumour necrosis factor-alpha (TNF-α)-treated endothelial monolayers: associations with clinical relapse and adhesion molecule expression, 155

WADSTRÖM, T. *see* BOGSTEDT, A.K.
WANG, J. *see* SATOH, M.
WATANABE, H. *see* ISHIYAMA, T.
WATANABE, K. *see* ISHIYAMA, T.
WATSON, C., WHITTAKER, S., SMITH, N., VORA, A.J., DUMONDE, D.C. & BROWN, K.A. IL-6 acts on endothelial cells to preferentially increase their adherence for lymphocytes, 112
WATSON, P.F. *see* AJJAN, R.A.
WEBSTER, A.D.B. *see* NORTH, M.E.
WEETMAN, A.P. *see* AJJAN, R.A.
WEICHSELBRAUN, I. *see* RIECKMANN, P.
WENISCH, C. WENISCH, H. PARSCHALK, B. VANIJANONTA, S. BURGMANN, H. EXNER, M. ZEDWITZ-LIEBENSTEIN, K. THALHAMMER, F. GEORGOPOULOS, A. GRANINGER, W. & LOOAREESUWAN, S. Elevated levels of soluble CD14 in serum of patients with acute *Plasmodium falciparum* malaria, 74
WENISCH, H. *see* WENISCH, C.
WHITTAKER, S. *see* WATSON, C.
WIESLANDER, J. *see* HELLMARK, T.
WILKINSON, R.J. *see* JURCEVIC, S.
WILLIAMS, J. O'DONOHUE & R. Immunological control in primary biliary cirrhosis: the cytokine story, 199
WINFIELD, J.B. *see* SATOH, M.
WOLF, H.M., HAUBER, I., GULLE, H., SAMSTAG, A., FISCHER, M.B., AHMAD, R.U. & EIBL, M.M. Anti-inflammatory properties of human serum IgA: induction of IL-1 receptor antagonist and FcαR (CD89)-mediated down-regulation of tumour necrosis factor-alpha (TNF-α) and IL-6 in human monocytes, 537
WÜRZNER, R. *see* TEIXEIRA, J.E.

YANG, J.J., TUTTLE, R., FALK, R.J. & JENNETTE, J.C. Frequency of anti-bactericidal/permeability-increasing protein (BPI) and anti-azurocidin in patients with renal disease, 125
YECHESKEL, G. *see* BAHARAV, E.
YOUINOU, P. *see* BAHARAV, E.
YOUINOU, P. *see* BOND, A.
YOUNG, S.P. *see* CARRUTHERS, D.M.
YSSEL, H. *see* FAITH, A.

ZACCONE, P. *see* DI MARCO, R.
ZAMBELLO, R., TRENTIN, L., ENTHAMMER, C., CIPRIANI, A., AGOSTINI, C. & SEMENZATO, G. Lysis of pulmonary fibroblasts by lymphokine (IL-2)-activated killer cells—a mechanism affecting the human lung microenvironment?, 383
ZANUSSI, S., SIMONELLI, C., D'ANDREA, M., CAFFAU, C., CLERICI, M., TIRELLI, U. & DE PAOLI, P. $CD8^+$ lymphocyte phenotype and cytokine production in long-term non-progressor and in progressor patients with HIV-1 infection, 220
ZEDWITZ-LIEBENSTEIN, K. *see* WENISCH, C.
ZHANG, Z.-X. *see* GABRIELLI, A.
ZIGELMAN, R. *see* BAHARAV, E.

Subject Index

28-kD antigen, 120

actin, 389
activation, 176
acute-phase proteins, 260, 529
adherence, 112, 155
adhesion molecules, 65, 155
adjuvants, 26
ageing, 544
alternative activation, 1
ankylosing spondylitis, 278
anti-CD28 MoAb, 31
anti-centromere antibodies, 285
anti-chromo antibodies, 285
anti-GBM antibodies, 504
anti-HBs antibodies, 52
anti-neutrophil cytoplasmic antibodies, 104
anti-neutrophil cytoplasmic autoantibodies, 120, 125
anti-RNA polymerase antibody, 468
anti-topoisomerase I antibody, 468
antibodies, 39
antibody, 480
antibody class and subclass, 213
anticardiolipin and antibodies, 475
antigen presentation, 397, 544
antimitochondrial antibodies, 266, 297
antipolysaccharide antibodies, 12
APC, 26
apoptosis, 31, 306, 389
asymptomatic infections, 69
autoantibodies, 84, 140, 460
autoantibodies and extracellular matrix, 132
autoantigen, 313, 468
autoepitope, 285
autoimmune disease, 266
autoimmune haemolytic anaemia, 313
autoimmunity, 84, 104, 306, 486
azurocidin, 125

β_2-glycoprotein I, 69
B cells, 360
B lymphocytes, 183
bactericidal/permeability-increasing protein, 125
BAL lymphocytes, 383
band 3, 313

C3b/C4b, 302
calcium signalling, 291
cancer, 529
Candida, 213
cathepsin G, 120
CD28, 220
CD28 expression, 409
CD4 cells, 169
$CD4^+$ T cell, 163
$CD4^+$ T cells, 31
$CD8^+$ lymphocytes, 220
CD95, 220
cell adhesion molecules, 344
cell-mediated immunity, 429
cellular response, 52
cellular responses, 245
Ch7 heptapeptide, 403
Chagas' disease, 450
Chlamydia trachomatis, 429
chromo domain, 285
chronic mucocutaneous candidiasis, 205, 213
class switching, 360
combined CD3 plus CD28 MoAb, 409
common variable immunodeficiency, 517
complement, 39, 191, 497, 511
CR1, 302, 497
Crohn's disease, 278
cross-reactive antigens, 422
cryoglobulinaemia, 59
Crytococcus neoformans, 436
CTL, 18
custocyte system, 1
cyclosporin A, 338
cyclosporine, 486
cytokines, 69, 205, 225, 245, 254, 429, 523, 551
cytolysis, 39
cytotoxic T cell, 353
cytotoxic T lymphocytes, 369
cytotoxicity, 183, 450, 480

dendritic cells, 1, 397, 544
deoxyspergualin, 338
diabetes, 330
diabetes-prone BB rat, 338
DNA-dependent protein kinase, 460
DNA-PKcs, 460

Echinococcus granulosus, 456
ELISA, 475
ELISPOT, 52
endothelial cells, 112
endothelium, 155
enterocolitis, 551
epitopes, 231
Epstein–Barr virus, 369
Epstein–Barr virus and monoclonal gammopathy of undetermined significance, 46
exercise, 238
extracellular matrix, 321

factor H, 511
Fas-mediated cytotoxicity, 163
FcαR, 537
fractionated antigens, 245

GAD65, 330
glomerulonephritis, 125, 321
glycosylation, 99
Goodpasture syndrome, 504
gp120, 225

Haemophilus influenzae type b, 422
Hashimoto's thyroiditis, 523
HBs vaccine, 52
Helicobacter pylori, 202
hepatitis B, 254
hepatitis C virus, 59
histamine, 376
HIV, 18, 31
HIV-1, 39, 409
HIV-1 non-progression, 220
HIV p24, 403
HLA-A11, 369
HLA-DR, 416
hsp, 231
HTB-176.10 cell, 389
HTLV-1, 39

human, 183
human monocytes, 537
human primary hepatocytes, 260
hydatid disease, 456
hypersensitivity pneumonitis, 169
hypoglycaemia, 443

i antigen, 183
idiotype, 422
IEC-6, 274
IgA, 537
IgA deficiency, 202
IL-1, 26
IL-1Ra, 537
IL-11, 260
IL-12, 353, 450
IL-2, 205, 383, 517, 529
IL-2 receptors, 383
IL-4, 205, 274, 556
IL-5, 456
IL-6, 112, 205, 260, 456
immune complexes, 497
immunity, 59
immunoassay, 140
immunogenic peptides, 369
immunoglobulin G, 99
immunoglobulin genes, 89
immunoglobulin isotypes, 456
immunoglobulin therapy, 266
immunoglobulins, 238
immunoregulation, 52
immunotherapy, 338
in vitro antibody response, 403
indo-1, 291
infection, 59, 238
inhibition, 225
insulin, 443
insulin-dependent diabetes mellitus, 338
interferon-gamma, 205, 376, 383, 403, 416, 450, 517
intestinal epithelial cell, 274
intestinal lymphocytes, 556
intracellular cytokines, 517
intraepithelial lymphocytes, 556
intrathyroidal lymphocytes, 523
iscoms, 26
isoelectric focusing, 422
isoelectric point, 321
isotype switching, 436

Ku antigen, 460

LAK cells, 383
leprosy, 65
leukaemia inhibitory factor, 260
liver biopsy, 254
lungs, 480
lupus, 132
lymphocyte, 529
lymphocytes, 112, 155
lymphoid tissue, 176
lymphokine-activated killer cells, 556
lymphokines, 344
lyticase, 79

macrophages, 1
malaria, 69, 443
melanoma, 353
meningococci, 511
MHC, 231
mice, 169
molecular weight polymorphism, 302
monoclonal antibody, 313
monoclonal antibodies, 183, 436
mononuclear phagocytes, 1
mood state, 238

MRL-+/+, 163
MRL*lpr*/*lpr*, 480
mRNA, 254, 344
multiple sclerosis, 155
Mycobacterium tuberculosis, 416

N-acetylglucosamine, 79
natural antibody, 422
natural killer cells, 376, 480
Neisseria meningitidis, 511
neutrophils, 321
newborn, 551
NK cells, 46
NOD mice, 330
nucleosome, 132
NZB mouse, 313

onchocerciasis, 245

peptide, 140, 416
peptide immunization, 18
peripheral arthritis, 278
phenotype, 176
phytohaemagglutinin, 291
Pityrosporum ovale, 79
Plasmodium falciparum, 69
Plasmodium falciparum malaria, 74
pneumococcal antibodies, 238
pneumococcal polysaccharide, 213
pneumococcal vaccine, 12
prevention, 330
primary biliary cirrhosis, 254, 266
prognostic marker, 409
proinflammatory cytokines, 537
proliferation, 274
protein catabolism, 191
proteinase, 3, 104
psoriasis, 79
pulmonary hypertension, 475
pyruvate dehydrogenase complex, 297

quantitative reverse transcriptase-polymerase chain reaction, 148

rat Th1 and Th2 cells, 486
receptor, 302
rheumatic diseases, 285
rheumatoid arthritis, 89, 99, 291
RMA cell, 389

SCID, 12
SCID mice, 266
SCID-PBL-hu, 12
scleroderma, 468
SENIEUR protocol, 544
sepsis, 551
septicaemia, 74
serine proteases, 321
serpins, 191
sICAM-1, 65
Sjögren's syndrome, 99
soluble CD14, 74
soluble IL-6 receptors, 205
somatic mutation, 360
specific antibody responses, 213
spleen, 306
survival, 529
synthetic peptides, 330, 504
systemic lupus erythematosus, 302, 306, 497
systemic sclerosis, 475

T cell function, 409
T cell receptor, 278
T cells, 225, 231, 416
T helper cell subsets, 245
T helper epitope, 18
T lymphocyte, 176, 291

T lymphocytes, 544
tetanus antigens, 213
tetanus toxoid, 544
Th1, 225
Th2 cells, 344
therapy, 65
thymus, 306, 486
thyroglobulin, 140
thyroid, 148
thyroid hormones, 140
tolerance, 397
transforming growth factor-beta, 104
tumour necrosis factor, 74, 155, 443, 529
tumour necrosis factor-alpha, 148, 517
tumour-infiltrating lymphocytes, 344
type IV collagen, 504
tyrosinase, 84

ulcerative colitis, 120

vaccine, 18
vaccines, 26
vasculitis, 104, 125, 163
Vβ repertoire, 31
V_H genes, 360
vitiligo, 84

Yersinia, 231